BioLineRx (BLRX) Non-Current Debt (2022 - 2025)

BioLineRx has reported Non-Current Debt over the past 4 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $4.5 million for Q4 2025, down 50.21% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (down 50.21% YoY), and the annual figure for FY2025 was $4.5 million, down 50.21%.
  • Non-Current Debt for Q4 2025 was $4.5 million at BioLineRx, down from $9.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for BLRX hit a ceiling of $9.0 million in Q4 2024 and a floor of $4.5 million in Q4 2025.
  • Median Non-Current Debt over the past 4 years was $7.6 million (2022), compared with a mean of $7.2 million.
  • Biggest five-year swings in Non-Current Debt: surged 35.15% in 2024 and later plummeted 50.21% in 2025.
  • BioLineRx's Non-Current Debt stood at $8.6 million in 2022, then fell by 23.16% to $6.6 million in 2023, then surged by 35.15% to $9.0 million in 2024, then plummeted by 50.21% to $4.5 million in 2025.
  • The last three reported values for Non-Current Debt were $4.5 million (Q4 2025), $9.0 million (Q4 2024), and $6.6 million (Q4 2023) per Business Quant data.